Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy

Current Cancer Drug Targets

Volumn 12, Issue 8, 2012, Pages 899-924

  Dumont, Francis J ^a   Bischoff, Pierre ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Autophagy; Cancer therapy; Ionizing radiation; mTOR signaling; mTORC1; mTORC2; Radiosensitization; Radiotherapy; Rapamycin

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS;

AUTOPHAGY; BREAST CARCINOMA; CANCER CELL; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; COMPLEX FORMATION; CYTOTOXICITY; ENZYME SUBUNIT; FIBROSARCOMA; GENE DISRUPTION; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IONIZING RADIATION; LIPOSARCOMA; NONHUMAN; PANCREAS CANCER; PROSTATE CARCINOMA; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

ANIMALS; AUTOPHAGY; CELL LINE, TUMOR; DNA REPAIR; HUMANS; MICE; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867823521     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912803251243     Document Type: Review

References (227)

1. Connell, P. P.; Hellman, S. Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res. 2009, 69, 383-392.
2. Jeggo, P.; Lavin, M. F. Cellular radiosensitivity: how much better do we understand it? Int. J. Radiat. Biol. 2009, 85, 1061-1081.
3. Bhide, S. A.; Nutting, C. M. Recent advances in radiotherapy. BMC Med. 2010, 8, 25.
4. Bischoff, P.; Altmeyer, A.; Dumont, F. Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers. Expert Opin. Ther. Pat. 2009, 19, 643-662.
5. Dumont, F.; Altmeyer, A.; Bischoff, P. Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches. Expert Opin. Ther. Pat. 2009, 19, 775-779.
6. Verheij, M.; Vens, C.; van Triest, B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist. Updat. 2010, 13, 29-43.
7. Begg, A. C.; Stewart, F. A.; Vens, C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 2011, 11, 239-253.
8. Abraham, R. T.; Eng, C. H. Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin. Ther. Targets 2008, 12, 209-222.
9. Zoncu, R.; Efeyan, A.; Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12, 31-35.
10. Sehgal, S. N.; Baker, H.; Vézina, C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 1975, 28, 727-732.
11. Eng, C. P.; Sehgal, S. N.; Vézina, C. Activity of rapamycin (AY-22,989) against transplanted tumors. J. Antibiot. (Tokyo) 1984, 37, 1231-1237.
12. Dumont, F. J.; Staruch, M. J.; Koprak, S. L.; Melino, M. R.; Sigal, N. H. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. 1990, 144, 251-258.
13. Sarbassov, D. D.; Ali, S. M.; Sengupta, S.; Sheen, J. H.; Hsu, P. P.; Bagley, A. F.; Markhard, A. L.; Sabatini, D. M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22, 159-168.
14. Lamming, D. W.; Ye, L.; Katajisto, P.; Goncalves, M. D.; Saitoh, M.; Stevens, D. M.; Davis, J. G.; Salmon, A. B.; Richardson, A.; Ahima, R. S.; Guertin, D. A.; Sabatini, D. M.; Baur, J. A. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012, 335, 1638-1643.
15. Caron, E.; Ghosh, S.; Matsuoka, Y.; Ashton-Beaucage, D.; Therrien, M.; Lemieux, S.; Perreault, C.; Roux, P. P.; Kitano, H. A comprehensive map of the mTOR signaling network. Mol. Syst. Biol. 2010, 6, 453.
16. Sengupta, S.; Peterson, T. R.; Sabatini, D. M. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 2010, 40, 310-322.
17. Ma, X. M.; Blenis, J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 2009, 10, 307-318.
18. Duvel, K.; Yecies, J. L.; Menon, S.; Raman, P.; Lipovsky, A. I.; Souza, A. L.; Triantafellow, E.; Ma, Q.; Gorski, R.; Cleaver, S.; Vander Heiden, M. G.; Mackeigan, J. P.; Finan, P. M.; Clish, C. B.; Murphy, L. O.; Manning, B. D. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39, 171-183.
19. Peña-Llopis, S.; Vega-Rubin-de-Celis, S.; Schwartz, J. C.; Wolff, N. C.; Tran, T. A.; Zou, L.; Xie, X. J.; Corey, D. R.; Brugarolas, J. Regulation of TFEB and V-ATPases by mTORC1. EMBO J. 2011, 30, 3242-3258.
20. Jung, C. H.; Ro, S. H.; Cao, J.; Otto, N. M.; Kim, D. H. mTOR regulation of autophagy. FEBS Lett. 2010, 584, 1287-1295.
21. Manning, B. D.; Cantley, L. C. AKT/PKB signaling: navigating downstream. Cell 2007, 129, 1261-1274.
22. Sancak, Y.; Bar-Peled, L.; Zoncu, R.; Markhard, A. L.; Nada, S.; Sabatini, D. M. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010, 141, 290-303.
23. Ellisen, L. W. Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle 2005, 4, 1500-1502.
24. DeYoung, M. P.; Horak, P.; Sofer, A.; Sgroi, D.; Ellisen, L. W. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008, 22, 239-251.
25. Budanov, A. V.; Karin, M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008, 134, 451-460.
26. Shaw, R. J. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol. (Oxf) 2009, 196, 65-80.
27. Kim, J.; Kundu, M.; Viollet, B.; Guan, K. L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13, 132-141.
28. Oh, W. J.; Jacinto, E. mTOR complex 2 signaling and functions. Cell Cycle 2011, 10, 2305-2316.
29. Gan, X.; Wang, J.; Su, B.; Wu, D. Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 2011, 286, 10998-11002.
30. Tato, I.; Bartrons, R.; Ventura, F.; Rosa, J. L. Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling. J. Biol. Chem. 2011, 286, 6128-6142.
31. Zinzalla, V.; Stracka, D.; Oppliger, W.; Hall, M. N. Activation of mTORC2 by association with the ribosome. Cell 2011, 144, 757-768.
32. Sparks, C. A.; Guertin, D. A. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010, 29, 3733-3744.
33. Menon, S.; Manning, B. D. Common corruption of the mTOR signaling network in human tumors. Oncogene 2009, 27, S43-51.
34. Courtney, K. D.; Corcoran, R. B.; Engelman, J. A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28, 1075-1083.
35. Mendoza, M. C.; Er, E. E.; Blenis, J. The Ras-ERK and PI3KmTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 2011, 36, 320-328.
36. Maurer, M. J.; Su, T.; Saal, L. H.; Koujak, S.; Hopkins, B. D.; Barkley, C. R.; Wu, J.; Nandula, S.; Dutta, B.; Xie, Y.; Chin, Y. R.; Kim, D. I.; Ferris, J. S.; Gruvberger-Saal, S. K.; Laakso, M.; Wang, X.; Memeo, L.; Rojtman, A.; Matos, T.; Yu, J. S.; C., C.-C.; Isola, J.; Terry, M. B.; Toker, A.; Mills, G. B.; Zhao, J. J.; Murty, V. V.; Hibshoosh, H.; Parsons, R. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res. 2009, 69, 6299-6306.
37. Lu, Z. H.; Shvartsman, M. B.; Lee, A. Y.; Shao, J. M.; Murray, M. M.; Kladney, R. D.; Fan, D.; Krajewski, S.; Chiang, G. G.; Mills, G. B.; Arbeit, J. M. Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res. 2010, 70, 3287-3298.
38. Shackelford, D. B.; Shaw, R. J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9, 563-575.
39. Sato, T.; Nakashima, A.; Guo, L.; Coffman, K.; Tamanoi, F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 2010, 29, 2746-2752.
40. Hardt, M.; Chantaravisoot, N.; Tamanoi, F. Activating mutations of TOR (target of rapamycin). Genes Cells 2011, 16, 141-151.
41. Yecies, J. L.; Manning, B. D. Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res. 2011, 71, 2815-2820.
42. Guba, M.; von Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel, S.; Hornung, M.; Bruns, C. J.; Zuelke, C.; Farkas, S.; Anthuber, M.; Jauch, K. W.; Geissler, E. K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 2002, 8, 128-135.
43. Du, R.; Lu, K. V.; Petritsch, C.; Liu, P.; Ganss, R.; Passegué, E.; Song, H.; Vandenberg, S.; RS, J.; Z, W.; G., B. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13, 206-220.
44. Zhou, H.; Huang, S. mTOR signaling in cancer cell motility and tumor metastasis. Crit. Rev. Eukaryot. Gene Expr. 2010, 20, 1-16.
45. Liu, L.; Luo, Y.; Chen, L.; Shen, T.; Xu, B.; Chen, W.; Zhou, H.; Han, X.; Huang, S. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J. Biol. Chem. 2010, 285, 38362-38373.
46. Gulhati, P.; Bowen, K. A.; Liu, J.; Stevens, P. D.; Rychahou, P. G.; Chen, M.; Lee, E. W.; Weiss, H. L.; O'Connor, K. L.; Gao, T.; Evers, B. M. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011, 71, 3246-3256.
47. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646-674.
48. Sehgal, S. N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 2003, 35, 7S-14S.
49. Dancey, J. mTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol. 2010, 7, 209-219.
50. Ciuffreda, L.; Di Sanza, C.; Incani, U. C.; Milella, M. The mTOR pathway: a new target in cancer therapy. Curr. Cancer Drug Targets 2010, 10, 484-495.
51. Yao, J. C.; Shah, M. H.; Ito, T.; Bohas, C. L.; Wolin, E. M.; Van Cutsem, E.; Hobday, T. J.; Okusaka, T.; Capdevila, J.; de Vries, E. G.; Tomassetti, P.; Pavel, M. E.; Hoosen, S.; Haas, T.; Lincy, J.; Lebwohl, D.; Öberg, K. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011, 364, 514-523.
52. Di Nicolantonio, F.; Arena, S.; Tabernero, J.; Grosso, S.; Molinari, F.; Macarulla, T.; Russo, M.; Cancelliere, C.; Zecchin, D.; Mazzucchelli, L.; Sasazuki, T.; Shirasawa S.; Geuna, M.; Frattini, M.; Baselga, J.; Gallicchio, M.; Biffo S.; Bardelli, A. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest. 2010, 120, 2858-2866.
53. Janku, F.; Tsimberidou, A. M.; Garrido-Laguna, I.; Wang, X.; Luthra, R.; Hong, D. S.; Naing, A.; Falchook, G. S.; Moroney, J. W.; Piha-Paul, S. A.; Wheler, J. J.; Moulder, S. L.; Fu, S.; Kurzrock, R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol. Cancer Ther. 2011, 10, 558-565.
54. Choo, A. Y.; Blenis, J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 2009, 8, 567-572.
55. OReilly, K. E.; Rojo, F.; She, Q. B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D. J.; Ludwig, D. L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66, 1500-1508.
56. Cloughesy, T. F.; Yoshimoto, K.; Nghiemphu, P.; Brown, K.; Dang, J.; Zhu, S.; Hsueh, T.; Chen, Y.; Wang, W.; Youngkin, D.; Liau, L.; Martin, N.; Becker, D.; Bergsneider, M.; Lai, A.; Green, R.; Oglesby, T.; Koleto, M.; Trent, J.; Horvath, S.; Mischel, P. S.; Mellinghoff, I. K.; Sawyers, C. L. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008, 5, e8.
57. Tabernero, J.; Rojo, F.; Calvo, E.; Burris, H.; Judson, I.; Hazell, K.; Martinelli, E.; Ramon y Cajal, S.; Jones, S.; Vidal, L.; Shand, N.; Macarulla, T.; Ramos, F. J.; Dimitrijevic, S.; Zoellner, U.; Tang, P.; Stumm, M.; Lane, H. A.; Lebwohl, D.; Baselga, J. Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 2008, 26, 1603-1610.
58. Efeyan, A.; Sabatini, D. M. mTOR and cancer: many loops in one pathway. Curr. Opin. Cell Biol. 2010, 22, 169-176.
59. Hsu, P. P.; Kang, S. A.; Rameseder, J.; Zhang, Y.; Ottina, K. A.; Lim, D.; Peterson, T. R.; Choi, Y.; Gray, N. S.; Yaffe, M. B.; Marto, J. A.; Sabatini, D. M. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 332, 1317-1322.
60. Yu, Y.; Yoon, S. O.; Poulogiannis, G.; Yang, Q.; Ma, X. M.; Villén, J.; Kubica, N.; Hoffman, G. R.; Cantley, L. C.; Gygi, S. P.; Blenis, J. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011, 332, 1322-1326.
61. Vilar, E.; Perez-Garcia, J.; Tabernero, J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol. Cancer Ther. 2011, 10, 395-403.
62. Wander, S. A.; Hennessy, B. T.; Slingerland, J. M. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J. Clin. Invest. 2011, 121, 1231-1241.
63. LoPiccolo, J.; Blumenthal, G. M.; Bernstein, W. B.; Dennis, P. A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 2008, 11, 32-50.
64. Wang, X.; Sun, S. Y. Enhancing mTOR-targeted cancer therapy. Expert Opin. Ther. Targets 2009, 13, 1193-1203.
65. Kurmasheva, R. T.; Dudkin, L.; Billups, C.; Debelenko, L. V.; Morton, C. L.; Houghton, P. J. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res. 2009, 69, 7662-7671.
66. Chang, Q.; Chen, E.; Hedley, D. W. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Cancer Biol. Ther. 2009, 8, 1893-1901.
67. Jaeger-Lansky, A.; Cejka, D.; Ying, L.; Preusser, M.; Hoeflmayer, D.; Fuereder, T.; Koehrer, S.; Wacheck, V. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. Cancer Biol. Ther. 2010, 9, 919-927.
68. Mondesire, W. H.; Jian, W.; Zhang, H.; Ensor, J.; Hung, M. C.; Mills, G. B.; Meric-Bernstam, F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 2004, 10, 7031-7042.
69. Beuvink, I.; Boulay, A.; Fumagalli, S.; Zilbermann, F.; Ruetz, S.; O'Reilly, T.; Natt, F.; Hall, J.; Lane, H. A.; Thomas, G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 25, 747-759.
70. Tanaka, K.; Sasayama, T.; Mizukawa, K.; Kawamura, A.; Kondoh, T.; Hosoda, K.; Fujiwara, T.; Kohmura, E. Specific mTOR inhibitor rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) in human U251 malignant glioma cells. J. Neurooncol. 2007, 84, 233-244.
71. Houghton, P. J.; Morton, C. L.; Gorlick, R.; Lock, R. B.; Carol, H.; Reynolds, C. P.; Kang, M. H.; Maris, J. M.; Keir, S. T.; Kolb, E. A.; Wu, J.; Wozniak, A. W.; Billups, C. A.; Rubinstein, L.; Smith, M. A. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol. Cancer Ther. 2010, 9, 101-112.
72. Contessa, J. N.; Hampton, J.; Lammering, G.; Mikkelsen, R. B.; Dent, P.; Valerie, K.; Schmidt-Ullrich, R. K. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 2002, 21, 4032-4041.
73. Valerie, K.; Yacoub, A.; Hagan, M. P.; Curiel, D. T.; Fisher, P. B.; Grant, S.; Dent, P. Radiation-induced cell signaling: inside-out and outside-in. Mol. Cancer Ther. 2007, 6, 789-801.
74. Wolfort, R.; de Benedetti, A.; Nuthalapaty, S.; Yu, H.; Chu, Q. D.; Li, B. D. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer. Surgery 2006, 140, 161-169.
75. Sunavala-Dossabhoy, G.; Fowler, M.; De Benedetti, A. Translation of the radioresistance kinase TLK1B is induced by gammairradiation through activation of mTOR and phosphorylation of 4EBP1. BMC Mol. Biol. 2004, 5, 1.
76. de Bruin, E. C.; Medema, J. P. Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat. Rev. 2008, 34, 737-749.
77. Paglin, S.; Hollister, T.; Delohery, T.; Hackett, N. M., M.; Sphicas, E.; Domingo, D.; Yahalom, J. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 2001, 61, 439-444.
78. Paglin, S.; Lee, N. Y.; Nakar, C.; Fitzgerald, M.; Plotkin, J.; Deuel, B.; Hackett, N.; McMahill, M.; Sphicas, E.; Lampen, N.; Yahalom, J. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res. 2005, 65, 11061-11070.
79. Tsujimoto, Y.; Shimizu, S. Another way to die: autophagic programmed cell death. Cell Death Differ. 2005, 12, 1528-1534.
80. Lefranc, F.; Facchini, V.; Kiss, R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 2007, 12, 1395-1403.
81. Jaboin, J. J.; Shinohara, E. T.; Moretti, L.; Yang, E. S.; Kaminski, J. M.; Lu, B. The role of mTOR inhibition in augmenting radiation induced autophagy. Technol. Cancer Res. Treat. 2007, 6, 443-447.
82. Williams, K. J.; Telfer, B. A.; Xenaki, D.; Sheridan, M. R.; Desbaillets, I.; Peters, H. J.; Honess, D.; Harris, A. L.; Dachs, G. U.; van der Kogel, A.; Stratford, I. J. Enhanced response to radiotherapy in tumours deficient in the function of hypoxiainducible factor-1. Radiother. Oncol. 2005, 75, 89-98.
83. Moeller, B. J.; Dewhirst, M. W. HIF-1 and tumour radiosensitivity. Br. J. Cancer 2006, 95, 1-5.
84. Dewhirst, M. W.; Cao, Y.; Moeller, B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer 2008, 8, 425-437.
85. Kaper, F.; Dornhoefer, N.; Giaccia, A. J. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res. 2006, 66, 1561-1569.
86. Cam, H.; Easton, J. B.; High, A.; Houghton, P. J. mTORC1 signaling under hypoxic conditions is controlled by ATMdependent phosphorylation of HIF-1alpha. Mol. Cell 2010, 40, 509-520.
87. Harada, H.; Itasaka, S.; Kizaka-Kondoh, S.; Shibuya, K.; Morinibu, A.; Shinomiya, K.; Hiraoka, M. The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose-and reoxygenation-dependent manner in irradiated tumors. J. Biol. Chem. 2009, 284, 5332-5342.
88. Kim, J. J.; Tannock, I. F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat. Rev. Cancer 2005, 5, 516-525.
89. Munshi, A.; Hobbs, M.; Meyn, R. E. Clonogenic cell survival assay. Methods Mol. Med. 2005, 110, 21-28.
90. Harrington, K. J.; Billingham, L. J.; Brunner, T. B.; Burnet, N. G.; Chan, C. S.; Hoskin, P.; Mackay, R. I.; Maughan, T. S.; Macdougall, J.; McKenna, W. G.; Nutting, C. M.; Oliver, A.; Plummer, R.; Stratford, I. J.; Illidge, T. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br. J. Cancer 2011, 105, 628-639.
91. Albert, J. M.; Kim, K. W.; Cao, C.; Lu, B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol. Cancer Ther. 2006, 5, 1183-1189.
92. No, M.; Choi, E. J.; Kim, I. A. Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance. Cancer Biol. Ther. 2009, 8, 2351-2361
93. Cao, C.; Subhawong, T.; Albert, J. M.; Kim, K. W.; Geng, L.; Sekhar, K. R.; Gi, Y. J.; Lu, B. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006, 66, 10040-10047.
94. Schiewer, M. J.; Den, R.; Hoang, D. T.; Augello, M. A.; Lawrence, Y. R.; Dicker, A. P.; Knudsen, K. E. mTOR is a selective effector of the radiation therapy response in androgen receptor positive prostate cancer. Endocr. Relat. Cancer 2012, 19, 1-12.
95. Kim, K. W.; Hwang, M.; Moretti, L.; Jaboin, J. J.; Cha, Y. I.; Lu, B. Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. Autophagy 2008, 4, 659-668.
96. Choi, E. J.; Ryu, Y. K.; Kim, S. Y.; Wu, H. G.; Kim, J. S.; Kim, I. H.; Kim, I. A. Targeting epidermal growth factor receptorassociated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Mol. Cancer Res. 2010, 8, 1027-1036.
97. Nagata, Y.; Takahashi, A.; Ohnishi, K.; Ota, I.; Ohnishi, T.; Tojo, T.; Taniguchi, S. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. Int. J. Oncol. 2010, 37, 1001-1010.
98. Lin, C. I.; Whang, E. E.; Donner, D. B.; Du, J.; Lorch, J.; He, F.; Jiang, X.; Price, B. D.; Moore, F. D.; Ruan, D. T. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol. Cancer Res. 2010, 8, 1217-1226.
99. Murphy, J. D.; Spalding, A. C.; Somnay, Y. R.; Markwart, S.; Ray, M. E.; Hamstra, D. A. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin. Cancer Res. 2009,15, 589-596.
100. Eshleman, J. S.; Carlson, B. L.; Mladek, A. C.; Kastner, B. D.; Shide, K. L.; Sarkaria, J. N. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 2002, 62, 7291-7297.
101. Shinohara, E. T.; Cao, C.; Niermann, K.; Mu, Y.; Zeng, F.; Hallahan, D. E.; Lu, B. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005, 24, 5414-5422.
102. Manegold, P. C.; Paringer, C.; Kulka, U.; Krimmel, K.; Eichhorn, M. E.; Wilkowski, R.; Jauch, K. W.; Guba, M.; Bruns, C. J. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin. Cancer Res. 2008, 14, 892-900.
103. Shinohara, E. T.; Maity, A.; Jha, N.; Lustig, R. A. Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck. Head Neck 2009, 31, 406-411.
104. Ekshyyan, O.; Rong, Y.; Rong, X.; Pattani, K. M.; Abreo, F.; Caldito, G.; Chang, J. K.; Ampil, F.; Glass, J.; Nathan, C. O. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol. Cancer Ther. 2009, 8, 2255-2265.
105. Kim, K. W.; Mutter, R. W.; Cao, C.; Albert, J. M.; Freeman, M.; Hallahan, D. E.; Lu, B. Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J. Biol. Chem. 2006, 281, 36883-36890.
106. Bandhakavi, S.; Kim, Y. M.; Ro, S. H.; Xie, H.; Onsongo, G.; Jun, C. B.; Kim, D. H.; Griffin, T. J. Quantitative nuclear proteomics identifies mTOR regulation of DNA damage response. Mol. Cell Proteomics 2010, 9, 403-414.
107. Jimeno, A.; Rudek, M. A.; Kulesza, P.; Ma, W. W.; Wheelhouse, J.; Howard, A.; Khan, Y.; Zhao, M.; Jacene, H.; Messersmith, W. A.; Laheru, D.; Donehower, R. C.; Garrett-Mayer, E.; Baker, S. D.; Hidalgo, M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J. Clin. Oncol. 2008, 26, 4172-4179.
108. Pawlik, T. M.; Keyomarsi, K. Role of cell cycle in mediating sensitivity to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59, 928-942.
109. Braunstein, S.; Badura, M. L.; Xi, Q.; Formenti, S. C.; Schneider, R. J. Regulation of protein synthesis by ionizing radiation. Mol. Cell Biol. 2009, 29, 5645-5656.
110. Weppler, S. A.; Krause, M.; Zyromska, A.; Lambin, P.; Baumann, M.; Wouters, B. G. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother. Oncol. 2007, 82, 96-104.
111. Ciccia, A.; Elledge, S. J. The DNA damage response: making it safe to play with knives. Mol. Cell 2010, 40, 179-204.
112. Pauwels, B.; Wouters, A.; Peeters, M.; Vermorken, J. B.; Lardon, F. Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation. Future Oncol. 2010, 6, 1485-1496.
113. Landsverk, K. S.; Patzke, S.; Rein, I. D.; Stokke, C.; Lyng, H.; De Angelis, P. M.; Stokke, T. Three independent mechanisms for arrest in G2 after ionizing radiation. Cell Cycle 2011, 10, 819-829.
114. Rodemann, H. P.; Dittmann, K.; Toulany, M. Radiation-induced EGFR-signaling and control of DNA-damage repair. Int. J. Radiat. Biol. 2007, 83, 781-791.
115. Meyn, R. E.; Munshi, A.; Haymach, J. V.; Milas, L.; Ang, K. K. Receptor signaling as a regulatory mechanism of DNA repair. Radiother. Oncol. 2009, 92, 316-322.
116. Toulany, M.; Kasten-Pisula, U.; Brammer, I.; Wang, S.; Chen, J.; Dittmann, K.; Baumann, M.; Dikomey, E.; Rodemann, H. P. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin. Cancer Res. 2006, 12, 4119-4126.
117. Chen, H.; Ma, Z.; Vanderwaal, R. P.; Feng, Z.; Gonzalez-Suarez, I.; Wang, S.; Zhang, J.; Roti Roti, J. L.; Gonzalo, S.; Zhang, J. The mTOR inhibitor rapamycin suppresses DNA double-strand break repair. Radiat Res. 2011, 175, 214-224.
118. Speirs, C. K.; Hwang, M.; Kim, S.; Li, W.; Chang, S.; Varki, V.; Mitchell, L.; Schleicher, S.; Lu, B. Harnessing the cell death pathway for targeted cancer treatment. Am. J. Cancer Res. 2011, 1, 43-61.
119. Harada, H.; Andersen, J. S.; Mann, M.; Terada, N.; Korsmeyer, S. J. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl Acad. Sci. USA 2001, 98, 9666-9670.
120. Vaira, V.; Lee, C. W.; Goel, H. L.; Bosari, S.; Languino, L. R.; Altieri, D. C. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 2007, 26, 2678-2684.
121. Meschini, S.; Condello, M.; Lista, P.; Arancia, G. Autophagy: Molecular mechanisms and their implications for anticancer therapies. Curr. Cancer Drug Targets 2011, 11, 257-379.
122. Yang, Z.; Klionsky, D. J. Mammalian autophagy: core molecular machinery and signaling regulation. Curr. Opin. Cell Biol. 2010, 22, 124-131.
123. Kroemer, G.; Mariño, G.; Levine, B. Autophagy and the integrated stress response. Mol. Cell 2010, 40, 280-293.
124. Kroemer, G.; Levine, B. Autophagic cell death: the story of a misnomer. Nat. Rev. Mol. Cell Biol. 2008, 9, 1004-1010.
125. Wu, W. K.; Coffelt, S. B.; Cho, C. H.; Wang, X. J.; Lee, C. W.; Chan, F. K.; Yu, J.; Sung, J. J. The autophagic paradox in cancer therapy. Oncogene 2012, 31, 939-953.
126. Shen, H. M.; Codogno, P. Autophagic cell death: Loch Ness monster or endangered species? Autophagy 2011, 7, 457-465.
127. Kang, R.; Zeh, H. J.; Lotze, M. T.; Tang, D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011, 18, 571-580.
128. Maiuri, M. C.; Zalckvar, E.; Kimchi, A.; Kroemer, G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2007, 8, 741-752.
129. Eisenberg-Lerner, A.; Bialik, S.; Simon, H. U.; Kimchi, A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ. 2009, 16, 966-975.
130. Zois, C. E.; Koukourakis, M. I. Radiation-induced autophagy in normal and cancer cells: towards novel cytoprotection and radiosensitization policies? Autophagy 2009, 5, 442-450.
131. Alexander, A.; Cai, S. L.; Kim, J.; Nanez, A.; Sahin, M.; MacLean, K. H.; Inoki, K.; Guan, K. L.; Shen, J.; Person, M. D.; Kusewitt, D.; Mills, G. B.; Kasta, M. B.; Walker, C. L. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc. Natl Acad. Sci. USA 2010.107, 4153-4158
132. Sanli, T.; Rashid, A.; Liu, C.; Harding, S.; Bristow, R. G.; Cutz, J. C.; Singh, G.; Wright, J.; Tsakiridis, T. Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int. J. Radiat. Biol. Biol. Phys. 2010, 78, 221-229.
133. Zannella, V. E.; Cojocari, D.; Hilgendorf, S.; Vellanki, R. N.; Chung, S.; Wouters, B. G.; Koritzinsky, M. AMPK regulates metabolism and survival in response to ionizing radiation. Radiother. Oncol. 2011, 99, 293-299.
134. Schleicher, S. M.; Moretti, L.; Varki, V.; Lu, B. Progress in the unraveling of the endoplasmic reticulum stress/autophagy pathway and cancer: implications for future therapeutic approaches. Drug Resist. Updat. 2010, 13, 79-86.
135. Verfaillie, T.; Salazar, M.; Velasco, G.; Agostinis, P. Linking ER stress to autophagy: potential implications for cancer therapy. Int. J. Cell Biol. 2010, 2010:930509.
136. Apel, A.; Herr, I.; Schwarz, H.; Rodemann, H. P.; Mayer, A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res. 2008, 68, 1485-1494.
137. Chaachouay, H.; Ohneseit, P.; Toulany, M.; Kehlbach, R.; Multhoff, G.; Rodemann, H. P. Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother. Oncol. 2011, 99, 287-292.
138. Ito, H.; Daido, S.; Kanzawa, T.; Kondo, S.; Kondo, Y. Radiationinduced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells. Int. J. Oncol. 2005, 26, 1401-1410.
139. Lomonaco, S. L.; Finniss, S.; Xiang, C.; Decarvalho, A.; Umansky, F.; Kalkanis, S. N.; Mikkelsen, T.; Brodie, C. The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int. J. Cancer 2009, 125, 717-722.
140. Abedin, M. J.; Wang, D.; McDonnell, M. A.; Lehmann, U.; Kelekar, A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ. 2007, 14, 500-510.
141. Stassi, G.; Todaro, M.; Zerilli, M.; Ricci-Vitiani, L.; Di Liberto, D.; Patti, M.; Florena, A.; Di Gaudio, F.; Di Gesù, G.; De Maria, R. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res. 2003, 63, 6784-6790.
142. Kuwahara, Y.; Oikawa, T.; Ochiai, Y.; Roudkenar, M. H.; Fukumoto, M.; Shimura, T.; Ohtake, Y.; Ohkubo, Y.; S, M.; Y, U.; M., F. Enhancement of autophagy is a potential modality for tumors refractory to radiotherapy. Cell Death Dis. 2011, 2, e177.
143. Moretti, L.; Kim, K. W.; Jung, D. K.; Willey, C. D.; Lu, B. Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor. Mol. Cancer Ther. 2009, 8, 1270-1279.
144. Kim, K. W.; Moretti, L.; Lu, B. M867, a novel selective inhibitor of caspase-3 enhances cell death and extends tumor growth delay in irradiated lung cancer models. PLoS One 2008, 3, e2275.
145. Kim, K. W.; Moretti, L.; Mitchell, L. R.; Jung, D. K.; Lu, B. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model. Clin. Cancer Res. 2009, 15, 6096-6105.
146. Malik, S. A.; Orhon, I.; Morselli, E.; Criollo, A.; Shen, S.; Mariño, G.; Benyounes, A.; Bénit, P.; Rustin, P.; Maiuri, M. C.; Kroemer, G. BH3 mimetics activate multiple pro-autophagic pathways. Oncogene 2011, 30, 3918-3929.
147. Zhuang, W.; Li, B.; Long, L.; Chen, L.; Huang, Q.; Liang, Z. Induction of autophagy promotes differentiation of gliomainitiating cells and their radiosensitivity. Int. J. Cancer 2011, 129, 2720-2731.
148. Benzina, S.; Altmeyer, A.; Malek, F.; Dufour, P.; Denis, J. M.; Gueulette, J.; Bischoff, P. High-LET radiation combined with oxaliplatin induce autophagy in U-87 glioblastoma cell. Cancer Lett. 2008, 264, 63-70.
149. Altmeyer, A.; Jung, A. C.; Ignat, M.; Benzina, S.; Denis, J. M.; Gueulette, J.; Noël, G.; Mutter, D.; Bischoff, P. Pharmacological enhancement of autophagy induced in a hepatocellular carcinoma cell line by high-LET radiation. Anticancer Res. 2010, 30, 303-310.
150. Mukubou, H.; Tsujimura, T.; Sasaki, R.; Ku, Y. The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation. Int. J. Oncol. 2010, 37, 821-828.
151. Kim, K. W.; Moretti, L.; Mitchell, L. R.; Jung, D. K.; Lu, B. Endoplasmic reticulum stress mediates radiation-induced autophagy by perk-eIF2alpha in caspase-3/7-deficient cells. Oncogene 2010, 29, 3241-3251.
152. Kim, K. W.; Speirs, C. K.; Jung, D. K.; Lu, B. The zinc ionophore PCI-5002 radiosensitizes non-small cell lung cancer cells by enhancing autophagic cell death. J. Thorac. Oncol. 2011, 6, 1542-1552.
153. Wilson, E. N.; Bristol, M. L.; Di, X.; Maltese, W. A.; Koterba, K.; Beckman, M. J.; Gewirtz, D. A. A switch between cytoprotective and cytotoxic autophagy in the radiosensitization of breast tumor cells by chloroquine and vitamin D. Horm. Cancer 2011, 2, 272-285.
154. Lisse, T. S.; Hewison, M. Vitamin D: a new player in the world of mTOR signaling. Cell Cycle 2011, 10, 1888-1889.
155. Dewaele, M.; Maes, H.; P., A. ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy. Autophagy 2010, 6, 838-854.
156. Levine, B.; Abrams, J. p53: The Janus of autophagy? Nat. Cell Biol. 2008, 10, 637-639.
157. Ohoka, N.; Yoshii, S.; Hattori, T.; Onozaki, K.; Hayashi, H. TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J. 2005, 24, 1243-1255.
158. Zalckvar, E.; Berissi, H.; Mizrachy, L.; Idelchuk, Y.; Koren, I.; Eisenstein, M.; Sabanay, H.; Pinkas-Kramarski, R.; Kimchi, A. DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy. EMBO Rep. 2009, 10, 285-292.
159. Hosoi, H.; Dilling, M. B.; Shikata, T.; Liu, L. N.; Shu, L.; Ashmun, R. A.; Germain, G. S.; Abraham, R. T.; Houghton, P. J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 1999, 59, 886-894.
160. Yu, L.; McPhee, C. K.; Zheng, L.; Mardones, G. A.; Rong, Y.; Peng, J.; Mi, N.; Zhao, Y.; Liu, Z.; Wan, F.; Hailey, D. W.; Oorschot, V.; Klumperman, J.; Baehrecke, E. H.; Lenardo, M. J. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 2010, 465, 942-946.
161. Shubassi, G.; Robert, T.; Vanoli, F.; Minucci, S.; Foiani, M. Acetylation: a novel link between double-strand break repair and autophagy. Cancer Res. 2012, 72, 1332-1335.
162. De Bacco, F.; Luraghi, P.; Medico, E.; Reato, G.; Girolami, F.; Perera, T.; Gabriele, P.; Comoglio, P. M.; Boccaccio, C. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J. Natl Cancer Inst. 2011, 103, 645-661.
163. Young, A. R.; Narita, M.; Ferreira, M.; Kirschner, K.; Sadaie, M.; Darot, J. F.; Tavaré, S.; Arakawa, S.; Shimizu, S.; Watt, F. M.; Narita, M. Autophagy mediates the mitotic senescence transition. Genes Dev. 2009, 23, 798-803.
164. Cao, Y.; Klionsky, D. J. Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein. Cell Res. 2007, 17, 839-849.
165. Gao, W.; Shen, Z.; Shang, L.; Wang, X. Upregulation of human autophagy-initiation kinase ULK1 by tumor suppressor p53 contributes to DNA-damage-induced cell death. Cell Death Differ. 2011, 18, 1598-1607.
166. Nyfeler, B.; Bergman, P.; Triantafellow, E.; Wilson, C. J.; Zhu, Y.; Radetich, B.; Finan, P. M.; Klionsky, D. J.; Murphy, L. O. Relieving autophagy and 4EBP1 from rapamycin resistance. Mol. Cell Biol. 2011, 31, 2867-2876.
167. Mao, X. W. A quantitative study of the effects of ionizing radiation on endothelial cells and capillary-like network formation. Technol. Cancer Res. Treat. 2006, 5, 127-134.
168. Edwards, E.; Geng, L.; Tan, J.; Onishko, H.; Donnelly, E.; Hallahan, D. E. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 2002, 62, 4671-4677.
169. Kruser, T. J.; Wheeler, D. L.; Armstrong, E. A.; Iida, M.; Kozak, K. R.; van der Kogel, A. J.; Bussink, J.; Coxon, A.; Polverino, A.; Harari, P. M. Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clin. Cancer Res. 2010, 16, 3639-3647.
170. Dormond, O.; Madsen, J. C.; Briscoe, D. M. The effects of mTORAkt interactions on anti-apoptotic signaling in vascular endothelial cells. J. Biol. Chem. 2007, 282, 23679-23686.
171. Guba, M.; Yezhelyev, M.; Eichhorn, M. E.; Schmid, G.; Ischenko, I.; Papyan, A.; Graeb, C.; Seeliger, H.; Geissler, E. K.; Jauch, K. W.; Bruns, C. J. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood 2005, 105, 4463-4469.
172. Mauceri, H. J.; Sutton, H. G.; Darga, T. E.; Kocherginsky, M.; Kochanski, J.; Weichselbaum, R. R.; Vokes, E. E. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. Oncol. Rep. 2012, 27, 1625-1629.
173. Bozec, A.; Etienne-Grimaldi, M. C.; Fischel, J. L.; Sudaka, A.; Toussan, N.; Formento, P.; Milano, G. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. Oral. Oncol. 2011, 47, 940-945.
174. Bozec, A.; Formento, P.; Lassalle, S.; Lippens, C.; Hofman, P.; Milano, G. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br. J. Cancer 2007, 97, 65-72.
175. Kim, I. A.; Bae, S. S.; Fernandes, A.; Wu, J.; Muschel, R. J.; McKenna, W. G.; Birnbaum, M. J.; Bernhard, E. J. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res. 2005, 65, 7902-7910.
176. Bozulic, L.; Surucu, B.; Hynx, D.; Hemmings, B. A. PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol. Cell 2008, 30, 203-213.
177. Brognard, J.; Clark, A. S.; Ni, Y.; Dennis, P. A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001, 61, 3986-3997.
178. Fan, Q. W.; Knight, Z. A.; Goldenberg, D. D.; Yu, W.; Mostov, K. E.; Stokoe, D.; Shokat, K. M.; Weiss, W. A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006, 9, 341-349.
179. Raynaud, F. I.; Eccles, S.; Clarke, P. A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L. M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; de Haven Brandon, A.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 2007, 67, 5840-5850.
180. Guillard, S.; Clarke, P. A.; Te Poele, R.; Mohri, Z.; Bjerke, L.; Valenti, M.; Raynaud, F.; Eccles, S. A.; Workman, P. Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle 2009, 8, 443-453.
181. Prevo, R.; Deutsch, E.; Sampson, O.; Diplexcito, J.; Cengel, K.; Harper, J.; O'Neill, P.; McKenna, W. G.; Patel, S.; Bernhard, E. J. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res. 2008, 68, 5915-5923.
182. Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chène, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M. M., L.; Finan, P.; Sellers, W.; García-Echeverría, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7, 1851-1863.
183. Konstantinidou, G.; Bey, E. A.; Rabellino, A.; Schuster, K.; Maira, M. S.; Gazdar, A. F.; Amici, A.; Boothman, D. A.; Scaglioni, P. P. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 2009, 69, 7644-7652.
184. Schnell, C. R.; Stauffer, F.; Allegrini, P. R.; O'Reilly, T.; McSheehy, P. M.; Dartois, C.; Stumm, M.; Cozens, R.; Littlewood-Evans, A.; García-Echeverría, C.; Maira, S. M. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 2008, 68, 6598-6607.
185. Liu, T. J.; Koul, D.; LaFortune, T.; Tiao, N.; Shen, R. J.; Maira, S. M.; Garcia-Echevrria, C.; Yung, W. K. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol. Cancer Ther. 2009, 8, 2204-2210.
186. Fokas, E.; Im, J. H.; Hill, S. A.; Yameen, S.; Stratford, M. R.; Beech, J. S.; Hackl, W.; Sauveur-Michel, M.; Bernhard, E. J.; McKenna, W. G.; Muschel, R. J. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res. 2012, 72, 239-248.
187. Kong, D.; Yaguchi, S.; Yamori, T. Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Biol. Pharm. Bull. 2009, 32, 297-300.
188. Azad, A.; Jackson, S.; Cullinane, C.; Natoli, A. L.; Neilsen, P. M.; Callen, D., F.; Maira, S. M.; Hackl, W.; McArthur, G. A.; Solomon, B. Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells. Mol. Cancer Res. 2011, 9, 1696-1707.
189. Xue, Q.; Hopkins, B.; Perruzzi, C.; Udayakumar, D.; Sherris, D.; Benjamin, L. E. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res. 2008, 68, 9551-9557.
190. Diaz, R.; Nguewa, P. A.; Diaz-Gonzalez, J. A.; Hamel, E.; Gonzalez-Moreno, O.; Catena, R.; Serrano, D.; M, R.; D, S.; A., C. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. Br. J. Cancer 2009, 100, 932-940.
191. Feldman, M. E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z. A.; Ruggero, D.; Shokat, K. M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 10, e38.
192. US National Institutes of Health, Clinical Trials Registry and Database. http://clinnicaltrials.gov (Accessed March 29, 2012).
193. Sankhala, K.; Mita, A.; Kelly, K.; Mahalingam, D.; Giles, F.; Mita, M. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol. 2009, 4, 135-142.
194. Sonis, S.; Treister, N.; Chawla, S.; Demetri, G.; Haluska, F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010, 116, 210-215.
195. Bourgier, C.; Massard, C.; Moldovan, C.; Soria, J. C.; Deutsch, E. Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect? Ann. Oncol. 2011, 22, 485-486.
196. Sheehan, J. P.; Shaffrey, M. E.; Gupta, B.; Larner, J.; Rich, J. N.; Park, D. M. Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncol. 2010, 6, 1591-1601.
197. Chang, S. M.; Wen, P.; Cloughesy, T.; Greenberg, H.; Schiff, D.; Conrad, C.; Fink, K.; Robins, H. I.; De Angelis, L.; Raizer, J.; Hess, K.; Aldape, K.; Lamborn, K. R.; Kuhn, J.; Dancey, J.; Prados, M. D.; Institute., N. A. B. T. C. a. t. N. C. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 2005, 23, 357-361.
198. Galanis, E.; Buckner, J. C.; Maurer, M. J.; Kreisberg, J. I.; Ballman, K.; Boni, J.; Peralba, J. M.; Jenkins, R. B.; Dakhil, S. R.; Morton, R. F.; Jaeckle, K. A.; Scheithauer, B. W.; Dancey, J.; Hidalgo, M.; Walsh, D. J.; Group., N. C. C. T. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 2005, 23, 5294-5304.
199. Sarkaria, J. N.; Galanis, E.; Wu, W.; Dietz, A. B.; Kaufmann, T. J.; Gustafson, M. P.; Brown, P. D.; Uhm, J. H.; Rao, R. D.; Doyle, L.; Giannini, C.; Jaeckle, K. A.; Buckner, J. C. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin. Cancer Res. 2010, 16, 5573-5580.
200. Sarkaria, J. N.; Galanis, E.; Wu, W.; Peller, P. J.; Giannini, C.; Brown, P. D.; Uhm, J. H.; McGraw, S.; Jaeckle, K. A.; Buckner, J. C. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 2010, 81, 468-475.
201. Prasad, G.; Sottero, T.; Yang, X.; Mueller, S.; James, C. D.; Weiss, W. A.; Polley, M. Y.; Ozawa, T.; Berger, M. S.; Aftab, D. T.; Prados, M. D.; Haas-Kogan, D. A. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro. Oncol. 2011, 13, 384-392.
202. Baas, P.; Belderbos, J. S.; van den Heuvel, M. Chemoradiation therapy in nonsmall cell lung cancer. Curr. Opin. Oncol. 2011, 23, 140-149.
203. Provencio, M.; Sánchez, A.; Garrido, P.; Valcárcel, F. New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin. Lung Cancer 2010, 11, 91-97.
204. Gridelli, C.; Maione, P.; Rossi, A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 2008, 13, 139-147.
205. Sarkaria, J. N.; Schwingler, P.; Schild, S. E.; Grogan, P. T.; Mladek, A. C.; Mandrekar, S. J.; Tan, A. D.; Kobayashi, T.; Marks, R. S.; Kita, H.; Miller, R. C.; Limper, A. H.; Leof, E. B. Phase I trial of sirolimus combined with radiation and cisplatin in nonsmall cell lung cancer. J. Thorac. Oncol. 2007, 2, 751-757.
206. Marur, S.; Forastiere, A. A. Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer. Curr. Opin. Oncol. 2010, 22, 206-211.
207. Cirri, P.; Chiarugi, P. Cancer associated fibroblasts: the dark side of the coin. Am. J. Cancer Res. 2011, 1, 482-497.
208. Bussolati, B.; Deregibus, M. C.; Camussi, G. Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies. Curr. Vasc. Pharmacol. 2010, 8, 220-232.
209. Sausville, E. A.; Burger, A. M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006, 66, 3351-3354.
210. Pickhard, A. C.; Margraf, J.; Knopf, A.; Stark, T.; Piontek, G.; Beck, C.; Boulesteix, A. L.; Scherer, E. Q.; Pigorsch, S.; Schlegel, J.; Arnold, W.; Reiter, R. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways. BMC Cancer 2011, 11, 388.
211. Patel, V.; Marsh, C. A.; Dorsam, R. T.; Mikelis, C. M.; Masedunskas, A.; Amornphimoltham, P.; Nathan, C. A.; Singh, B.; Weigert, R.; Molinolo, A. A.; Gutkind, J. S. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res. 2011, 71, 7103-7112.
212. Apetoh, L.; Tesniere, A.; Ghiringhelli, F.; Kroemer, G.; Zitvogel, L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008, 68, 4026-4030.
213. Takeshima, T.; Chamoto, K.; Wakita, D.; Ohkuri, T.; Togashi, Y.; Shirato, H.; Kitamura, H.; Nishimura, T. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 2010.70, 2697-2706.
214. Altmeyer, A.; Ignat, M.; Denis, J. M.; Messaddeq, N.; Gueulette, J.; Mutter, D.; Bischoff, P. Cell death after high-LET irradiation in orthotopic human hepatocellular carcinoma in vivo. In Vivo 2011, 25, 1-9.
215. Mordant, P.; Loriot, Y.; Lahon, B.; Castier, Y.; Lesèche, G.; Soria, J. C.; Vozenin, M. C.; Decraene, C.; Deutsch, E. Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells. PLoS One 2011, 6, e26073.
216. Wang, X.; Zhan, Y.; Zhao, L.; Alvarez, J.; Chaudhary, I.; Zhou, B. B.; Abraham, R. T.; Feuerstein, G. Z. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin Inhibitor, temsirolimus, in a preclinical mammary carcinoma oncomouse model: a translational medicine study in support for early clinical development. J. Pharmacol. Exp. Ther. 2011, 339, 421-429.
217. Politi, K.; Pao, W. How genetically engineered mouse tumor models provide insights into human cancers. J. Clin. Oncol. 2011, 29, 2273-2281.
218. Shen, S.; Kepp, O.; Kroemer, G. The end of autophagic cell death? Autophagy 2012, 8, 1-3.
219. Gewirtz, D. A. Autophagy, senescence and tumor dormancy in cancer therapy. Autophagy 2009, 5, 1232-1234.
220. Davalos, A. R.; Coppe, J. P.; Campisi, J.; Desprez, P. Y. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev. 2010, 29, 283-283.
221. Lu, Z.; Luo, R. Z.; Lu, Y.; Zhang, X.; Yu, Q.; Khare, S.; Kondo, S.; Kondo, Y.; Yu, Y.; Mills, G. B.; Liao, W. S.; Bast, R. C. Jr. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J. Clin. Invest. 2008, 118, 3917-3929.
222. Leontieva, O. V.; Demidenko, Z. N.; Gudkov, A. V.; Blagosklonny, M. V. Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin. PLoS One 2011, 6, e26126.
223. Back, J. H.; Rezvani, H. R.; Zhu, Y.; Guyonnet-Duperat, V.; Athar, M.; Ratner, D.; Kim, A. L. Cancer cell survival following DNA damage-mediated premature senescence is regulated by mammalian target of rapamycin (mTOR)-dependent inhibition of sirtuin 1. J. Biol. Chem. 2011, 286, 19100-19108.
224. Krause, M.; Yaromina, A.; Eicheler, W.; Koch, U.; Baumann, M. Cancer stem cells: targets and potential biomarkers for radiotherapy. Clin. Cancer Res. 2011, 17, 7224-7229.
225. Welsh, J. S. Basics of particle therapy: introduction to hadrons. Am. J. Clin. Oncol. 2008, 31, 493-495.
226. Hamada, N.; Imaoka, T.; Masunaga, S.; Ogata, T.; Okayasu, R.; Takahashi, A.; Kato, T. A.; Kobayashi, Y.; Ohnishi, T.; Ono, K.; Shimada, Y.; Teshima, T. Recent advances in the biology of heavyion cancer therapy. J. Radiat. Res. (Tokyo) 2010, 51, 365-383.
227. Stahl, S.; Fung, E.; Adams, C.; Lengqvist, J.; Mörk, B.; Stenerlöw, B.; Lewensohn, R.; Lehtiö, J.; Zubarev, R.; Viktorsson, K. Proteomics and pathway analysis identifies JNK signaling as critical for high linear energy transfer radiation-induced apoptosis in non-small lung cancer cells. Mol. Cell Proteomics 2009, 8, 1117-1129.